Results 161 to 169 of about 15,511 (169)

Risk of cardiovascular disease associated with exposure to abacavir among individuals with HIV: A systematic review and meta-analyses of results from 17 epidemiologic studies

International Journal of Antimicrobial Agents, 2018
Sanjiv M Baxi, Kunchok Dorjee, Craig Steinmaus   +2 more
exaly  

Genetic variations in HLA-B region and hypersensitivity reactions to abacavir

Lancet, The, 2002
William R Spreen, Seth Hetherington, Allen D Roses   +2 more
exaly  

Abacavir and cardiovascular disease: A critical look at the data

Antiviral Research, 2016
Josep M Llibre
exaly  

Epidemiological risk factors for hypersensitivity reactions to abacavir*

HIV Medicine, 2003
Asma Ahmed
exaly  

Abacavir Hypersensitivity Reaction: an Update

Annals of Pharmacotherapy, 2008
Christine A Hughes
exaly  

A Review of the Pharmacokinetics of Abacavir

Clinical Pharmacokinetics, 2012
exaly  

A Pilot Study of Abacavir/Lamivudine and Raltegravir in Antiretroviral-Naïve HIV-1–Infected Patients: 48-Week Results of the SHIELD Trial

HIV Clinical Trials, 2010
Benjamin Young, Edwin Dejesus, Belinda Ha   +2 more
exaly  

Weight related differences in the pharmacokinetics of abacavir in HIV-infected patients

British Journal of Clinical Pharmacology, 2005
Nicolas Dupin, Dominique Salmon, V Jullien   +2 more
exaly  

Microbial biodegradation of abacavir: Isolation of sp. A1 and elucidation of novel degradation pathways

Chemical Engineering Journal

exaly